The global point-of-care molecular diagnostics market is expanding as healthcare providers increasingly adopt rapid and accurate testing solutions that deliver results near the patient. These technologies detect genetic material from pathogens and other biological samples, helping clinicians identify diseases and make timely treatment decisions. Unlike conventional laboratory testing, point-of-care molecular diagnostics can reduce turnaround times and support testing in hospitals, clinics, urgent care centers, decentralized laboratories, and home-care settings. Rising infectious disease prevalence, demand for decentralized healthcare, and advances in portable PCR and multiplex testing technologies are supporting market growth.

Download a free sample copy of the Point Of Care Molecular Diagnostics market report to understand detailed coverage and inclusions in the final report

Market Size and Growth Projections

The global point-of-care molecular diagnostics market was valued at USD 8.7 billion in 2025. It is estimated to reach USD 9.3 billion in 2026 and is projected to reach USD 14.5 billion by 2033, registering a compound annual growth rate (CAGR) of 6.6% from 2026 to 2033. North America dominated the market in 2025, supported by advanced healthcare infrastructure, established diagnostic companies, and growing adoption of rapid molecular testing.

Key Market Data (2025 Projections)

• Market Size (2025): USD 8.7 billion
• Market Size (2026): USD 9.3 billion
• Projected Value (2033): USD 14.5 billion
• Market CAGR:6% from 2026 to 2033
• Dominant Region: North America, holding 45.4% revenue share in 2025
• Leading Application: Infectious diseases, with 47.0% revenue share in 2025
• Leading Technology: PCR-based testing, with 66.0% revenue share in 2025
• Leading Test Location: Over-the-counter (OTC), with 52.3% revenue share in 2025
• Leading End Use: Decentralized laboratories, with 42.8% revenue share in 2025
• Fastest-Growing Region: Asia Pacific

Core Applications and Impact

Infectious disease testing represented the largest application segment, accounting for 47.0% of market revenue in 2025. Point-of-care molecular platforms are used to detect respiratory infections, influenza, HIV, hepatitis, tuberculosis, sexually transmitted infections, and other conditions. Rapid identification of pathogens helps healthcare professionals make timely treatment decisions and supports infection control, particularly in emergency departments and outpatient settings.

The technology is also gaining relevance in oncology, prenatal testing, hematology, and endocrinology. Molecular testing can help identify genetic markers and disease-related changes, supporting more informed clinical decisions. In prenatal care, molecular diagnostic methods can contribute to the detection of selected genetic conditions, while oncology applications support biomarker analysis and personalized treatment strategies.

Decentralized testing also improves access to diagnostics in community clinics, remote healthcare facilities, and resource-limited settings. Home-based molecular testing can provide greater convenience and privacy for patients who need accessible screening and monitoring solutions.

Go Deeper! Ask Prism AI

about the Global Point Of Care Molecular Diagnostics Market. Get instant answers to questions related to market sizing, growth drivers & their impact, and more.

Emerging Core Trends

Portable and Cartridge-Based Systems: Compact molecular diagnostic platforms with self-contained cartridges are gaining adoption. These systems simplify sample processing, reduce manual handling, and support testing outside centralized laboratories.

Multiplex Testing: Healthcare providers are increasingly adopting tests capable of detecting multiple pathogens from a single sample. Multiplex testing can help distinguish between infections with similar symptoms and support faster clinical decisions.

Advancements in PCR Technology: PCR-based systems remain important because of their sensitivity, reliability, and broad clinical applications. Portable thermal cyclers and simplified workflows are making molecular testing more accessible in decentralized settings.

Genetic Sequencing and Personalized Medicine: Advances in sequencing technologies are creating opportunities for faster genetic analysis and more targeted diagnostic approaches. These developments may support applications in infectious disease identification, oncology, and precision medicine.

Home-Based Molecular Testing: Demand for convenient and accessible testing is encouraging manufacturers to develop user-friendly platforms and simplified sample collection systems for home-care applications.

Geographical Landscape

North America dominated the market with a 45.4% revenue share in 2025. The region benefits from advanced healthcare infrastructure, established diagnostic networks, strong investment in medical technology, and widespread adoption of rapid testing. The U.S. is a major contributor, supported by demand for infectious disease testing and the presence of leading diagnostic manufacturers.

Europe represents an important market due to established healthcare systems, growing demand for rapid diagnosis, and increasing adoption of decentralized testing technologies. Countries such as Germany, the UK, and France are investing in advanced diagnostic solutions for hospitals, clinics, and community healthcare settings.

Asia Pacific is expected to register the fastest growth during the forecast period. Rising healthcare expenditure, expanding primary care infrastructure, increasing infectious disease burden, and growing awareness of early diagnosis are supporting demand. China, India, Japan, South Korea, and Australia represent important regional markets.

Latin America offers growth opportunities through expanding healthcare access and demand for rapid infectious disease testing. In the Middle East and Africa, investments in healthcare infrastructure and decentralized diagnostic services are creating opportunities for portable molecular testing platforms.

Looking for more specific insights? Customize this report to suite your business needs

Top Industry Players

The competitive landscape includes global diagnostic companies and specialized molecular testing technology providers. Major industry participants include:

• F. Hoffmann-La Roche Ltd.
• Abbott
• QIAGEN N.V.
• Danaher Corporation
• bioMérieux SA
• OraSure Technologies, Inc.
• binx health, inc.
• QuidelOrtho Corporation

Competition is focused on improving test accuracy, reducing turnaround times, expanding test menus, and developing compact diagnostic platforms. Companies are also investing in multiplex assays, portable PCR systems, regulatory approvals, and strategic partnerships to strengthen their market positions.

Overall, the point-of-care molecular diagnostics market is moving toward faster, portable, and more accessible testing solutions. Growing demand for infectious disease detection, decentralized healthcare, multiplex testing, and home-based diagnostics is expected to support market expansion through 2033.

Make informed decisions using comprehensive facility-level intelligence. Sign up @ https://www.grandviewresearch.com/horizon/hospital-database

About us:
Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.